Spots Global Cancer Trial Database for neurofibromatosis 2
Every month we try and update this database with for neurofibromatosis 2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Resiliency Training for Patients With NF2 Via Videoconferencing With Skype | NCT02811718 | Neurofibromatos... | Stress Manageme... Stress Manageme... | 18 Years - | Massachusetts General Hospital | |
| Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients | NCT01490476 | Neurofibromatos... | RAD001 | 15 Years - | Assistance Publique - Hôpitaux de Paris | |
| Reliability of Functional Outcome Measures in Neurofibromatosis 2 | NCT03617276 | Neurofibromatos... | 16 Years - | Guy's and St Thomas' NHS Foundation Trust | ||
| Neurofibromatosis (NF) Registry Portal | NCT01885767 | Neurofibromatos... Neurofibromatos... Schwannomatosis | - | The Children's Tumor Foundation | ||
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | NCT02831257 | Neurofibromatos... Meningioma | AZD2014 | 18 Years - | Massachusetts General Hospital | |
| PTC299 for Treatment of Neurofibromatosis Type 2 | NCT00911248 | Neurofibromatos... | PTC299 | 18 Years - | PTC Therapeutics | |
| Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype | NCT02298270 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | The Relaxation ... | 18 Years - | Massachusetts General Hospital | |
| Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing | NCT03406208 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | Stress and Symp... Stress and Symp... | 18 Years - | Massachusetts General Hospital | |
| NF2 Natural History Consortium | NCT00004483 | Schwannoma, Ves... Neurofibromatos... Meningioma | 5 Years - | Office of Rare Diseases (ORD) | ||
| Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | NCT00973739 | Neurofibromatos... Vestibular Schw... | Lapatinib | 4 Years - 80 Years | NYU Langone Health | |
| Study of Aspirin in Patients With Vestibular Schwannoma | NCT03079999 | Vestibular Schw... Acoustic Neurom... Neurofibromatos... | Aspirin Placebo | 12 Years - | Massachusetts Eye and Ear Infirmary | |
| An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors | NCT00030043 | Neurofibromatos... | Penetrating aud... | 18 Years - | FDA Office of Orphan Products Development | |
| Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors | NCT03095248 | Neurofibromatos... Vestibular Schw... Meningioma Ependymoma Glioma | Selumetinib | 3 Years - 45 Years | Children's Hospital Medical Center, Cincinnati | |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | NCT02831257 | Neurofibromatos... Meningioma | AZD2014 | 18 Years - | Massachusetts General Hospital | |
| An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors | NCT00030043 | Neurofibromatos... | Penetrating aud... | 18 Years - | FDA Office of Orphan Products Development | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | NCT00973739 | Neurofibromatos... Vestibular Schw... | Lapatinib | 4 Years - 80 Years | NYU Langone Health | |
| Concentration and Activity of Lapatinib in Vestibular Schwannomas | NCT00863122 | Vestibular Schw... NF2 Neurofibromatos... Acoustic Neurom... Auditory Tumor | lapatinib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | NCT00973739 | Neurofibromatos... Vestibular Schw... | Lapatinib | 4 Years - 80 Years | NYU Langone Health | |
| Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype | NCT02298270 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | The Relaxation ... | 18 Years - | Massachusetts General Hospital | |
| Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype | NCT02298270 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | The Relaxation ... | 18 Years - | Massachusetts General Hospital | |
| Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 | NCT00004437 | Neurofibromatos... | Multichannel Au... | 12 Years - | FDA Office of Orphan Products Development | |
| PTC299 for Treatment of Neurofibromatosis Type 2 | NCT00911248 | Neurofibromatos... | PTC299 | 18 Years - | PTC Therapeutics | |
| Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing | NCT03406208 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | Stress and Symp... Stress and Symp... | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
